Multaq (dronedarone) - Important Safety Information from Sanofi Aventis as approved by the Irish Medicines Board
04 October 2011
The European Medicines Agency's Committee for Medical Products for Human Use (CHMP) has completed its assessment of the benefits and risks of treatment with Multaq (dronedarone). As a result, the Multaq Summary of Product Characteristics (SmPC) has been modified.
Sanofi Aventis Multaq DHCP Letter 04.10.11.pdf